- Home
- GLPG vs ULCC Comparison
GLPG vs ULCC Comparison
Compare GLPG & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- ULCC
- Stock Information
- Founded
- GLPG 1999
- ULCC 1994
- Country
- GLPG Belgium
- ULCC United States
- Employees
- GLPG N/A
- ULCC N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- ULCC Air Freight/Delivery Services
- Sector
- GLPG Health Care
- ULCC Consumer Discretionary
- Exchange
- GLPG Nasdaq
- ULCC Nasdaq
- Market Cap
- GLPG 1.8B
- ULCC 1.9B
- IPO Year
- GLPG 2005
- ULCC 2021
- Fundamental
- Price
- GLPG $26.74
- ULCC $7.94
- Analyst Decision
- GLPG Sell
- ULCC Hold
- Analyst Count
- GLPG 5
- ULCC 11
- Target Price
- GLPG $26.75
- ULCC $7.41
- AVG Volume (30 Days)
- GLPG 355.9K
- ULCC 3.3M
- Earning Date
- GLPG 02-12-2025
- ULCC 02-07-2025
- Dividend Yield
- GLPG N/A
- ULCC N/A
- EPS Growth
- GLPG N/A
- ULCC N/A
- EPS
- GLPG 1.16
- ULCC 0.37
- Revenue
- GLPG $285,380,474.00
- ULCC $3,775,000,000.00
- Revenue This Year
- GLPG $2.78
- ULCC $17.35
- Revenue Next Year
- GLPG $1.62
- ULCC $12.48
- P/E Ratio
- GLPG $23.02
- ULCC $21.46
- Revenue Growth
- GLPG 14.99
- ULCC 5.18
- 52 Week Low
- GLPG $22.36
- ULCC $2.79
- 52 Week High
- GLPG $37.22
- ULCC $10.26
- Technical
- Relative Strength Index (RSI)
- GLPG 71.20
- ULCC 44.78
- Support Level
- GLPG $26.49
- ULCC $8.36
- Resistance Level
- GLPG $27.48
- ULCC $9.44
- Average True Range (ATR)
- GLPG 0.66
- ULCC 0.64
- MACD
- GLPG 0.54
- ULCC -0.12
- Stochastic Oscillator
- GLPG 85.55
- ULCC 7.20
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers.